Denali Therapeutics Inc. (DNLI) › Shareholders' EquityDenali Therapeutics Inc. (DNLI) — Shareholders' EquityAnnual figures by period end, from SEC filings.2015-12-31: -$15.63M2016-12-31: -$94.15M2017-12-31: $465.80M2018-12-31: $546.85M2019-12-31: $394.89M2020-12-31: $1.15B2021-12-31: $962.29M2022-12-31: $1.04B2023-12-31: $1.03B2024-12-31: $1.23B2025-12-31: $1.01B$1.01B2015-12-31Shareholders' Equity (USD)2025-12-31Period endedShareholders' EquityChange YoYSource filing2025-12-31$1.01B-17.6%2026-02-26Balance as of period end2024-12-31$1.23B+19.3%2026-02-26Balance as of period end2023-12-31$1.03B-1.1%2026-02-26Balance as of period end2022-12-31$1.04B+8.3%2026-02-26Balance as of period end2021-12-31$962.29M-16.4%2025-02-27Balance as of period end2020-12-31$1.15B+191.4%2024-02-28Balance as of period end2019-12-31$394.89M-27.8%2023-02-27Balance as of period end2018-12-31$546.85M+17.4%2022-02-28Balance as of period end2017-12-31$465.80M—2021-02-26Balance as of period end2016-12-31-$94.15M—2020-02-27Balance as of period end2015-12-31-$15.63M—2019-03-12Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)